These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 37363820)

  • 41. Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class.
    Weaver A; Bossaer JB
    J Oncol Pharm Pract; 2021 Apr; 27(3):702-710. PubMed ID: 33375902
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [New European approvals: Pemigatinib - cholangiocarcinoma with a FGFR2 fusion or rearrangement].
    Delaye M; Pernot S
    Bull Cancer; 2021 May; 108(5):446-447. PubMed ID: 33931169
    [No Abstract]   [Full Text] [Related]  

  • 43. EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.
    Wu Q; Zhen Y; Shi L; Vu P; Greninger P; Adil R; Merritt J; Egan R; Wu MJ; Yin X; Ferrone CR; Deshpande V; Baiev I; Pinto CJ; McLoughlin DE; Walmsley CS; Stone JR; Gordan JD; Zhu AX; Juric D; Goyal L; Benes CH; Bardeesy N
    Cancer Discov; 2022 May; 12(5):1378-1395. PubMed ID: 35420673
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oncogenic RAS Drives Resistance to Pemigatinib in Cholangiocarcinoma Harboring a FGFR2 Delins Disrupting Ligand Binding.
    Lim M; Lynch PT; Bai X; Hsiehchen D
    JCO Precis Oncol; 2023 Jan; 7():e2200340. PubMed ID: 36634295
    [No Abstract]   [Full Text] [Related]  

  • 45. FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements.
    Gandhy SU; Casak SJ; Mushti SL; Cheng J; Subramaniam S; Zhao H; Zhao M; Bi Y; Liu G; Fan J; Adeniyi O; Charlab R; Kufrin D; Thompson MD; Jarrell K; Auth D; Lemery SJ; Pazdur R; Kluetz PG; Fashoyin-Aje LA
    Clin Cancer Res; 2023 Oct; 29(20):4027-4031. PubMed ID: 37289037
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Futibatinib: A Potent and Irreversible Inhibitor of Fibroblast Growth Factor Receptors for Treatment of the Bile Duct Cancer.
    De SK
    Curr Med Chem; 2024; 31(6):666-670. PubMed ID: 37062061
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma.
    Wu Q; Ellis H; Siravegna G; Michel AG; Norden BL; Fece de la Cruz F; Balasooriya ER; Zhen Y; Silveira VS; Che J; Corcoran RB; Bardeesy N
    Clin Cancer Res; 2024 Jan; 30(1):198-208. PubMed ID: 37843855
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma.
    Zhang Z; Wang G; Du L; Zhao J; Pan L; Zhang G; Wang F; Liu R
    Front Immunol; 2023; 14():1124482. PubMed ID: 37292215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FDFT1/FGFR2 rearrangement: A newly identified anlotinib-sensitive FGFR2 variant in cholangiocarcinoma.
    Huang C; Wen Q; Chen J; Zhong H; Xiang X; Xiong J; Deng J
    Cancer Treat Res Commun; 2022; 31():100568. PubMed ID: 35477128
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel precision therapies for cholangiocarcinoma: an overview of clinical trials.
    Uson Junior PLS; Bearss J; Babiker HM; Borad MJ
    Expert Opin Investig Drugs; 2023 Jan; 32(1):69-75. PubMed ID: 36714945
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Not Available].
    Mas L; Perrier A; Coulet F; Bachet JB
    Bull Cancer; 2022 Nov; 109(11S):11S28-11S34. PubMed ID: 36535760
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress.
    Gadaleta-Caldarola G; Rizzo A; Dadduzio V; Lombardi L; Gadaleta-Caldarola A; Infusino S; Cusmai A; Citrigno C; Palmiotti G
    Curr Oncol; 2022 Oct; 29(10):7925-7931. PubMed ID: 36290903
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of molecular genetics in the clinical management of cholangiocarcinoma.
    Normanno N; Martinelli E; Melisi D; Pinto C; Rimassa L; Santini D; Scarpa A
    ESMO Open; 2022 Jun; 7(3):100505. PubMed ID: 35696744
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma.
    Botrus G; Raman P; Oliver T; Bekaii-Saab T
    Expert Opin Investig Drugs; 2021 Apr; 30(4):309-316. PubMed ID: 33307867
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy.
    Chueh CH; Tsai YW; Chen ZR; Shiu MN; Wen YW; Chiang NJ
    Pharmacoeconomics; 2023 Mar; 41(3):307-319. PubMed ID: 36575331
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Futibatinib for cholangiocarcinomas with a FGFR2 fusion or rearrangement, locally advanced or metastatic].
    Noé C; Edeline J
    Bull Cancer; 2023 Oct; 110(10):985-986. PubMed ID: 37500387
    [No Abstract]   [Full Text] [Related]  

  • 57. Targeting Fibroblast Growth Factor Receptor Pathway: Precision Medicine for Biliary Cancer and Beyond.
    Uson Junior PLS; Borad MJ
    Semin Liver Dis; 2023 May; 43(2):218-225. PubMed ID: 36882151
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
    Borad MJ; Champion MD; Egan JB; Liang WS; Fonseca R; Bryce AH; McCullough AE; Barrett MT; Hunt K; Patel MD; Young SW; Collins JM; Silva AC; Condjella RM; Block M; McWilliams RR; Lazaridis KN; Klee EW; Bible KC; Harris P; Oliver GR; Bhavsar JD; Nair AA; Middha S; Asmann Y; Kocher JP; Schahl K; Kipp BR; Barr Fritcher EG; Baker A; Aldrich J; Kurdoglu A; Izatt T; Christoforides A; Cherni I; Nasser S; Reiman R; Phillips L; McDonald J; Adkins J; Mastrian SD; Placek P; Watanabe AT; Lobello J; Han H; Von Hoff D; Craig DW; Stewart AK; Carpten JD
    PLoS Genet; 2014 Feb; 10(2):e1004135. PubMed ID: 24550739
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
    Wang Y; Ding X; Wang S; Moser CD; Shaleh HM; Mohamed EA; Chaiteerakij R; Allotey LK; Chen G; Miyabe K; McNulty MS; Ndzengue A; Barr Fritcher EG; Knudson RA; Greipp PT; Clark KJ; Torbenson MS; Kipp BR; Zhou J; Barrett MT; Gustafson MP; Alberts SR; Borad MJ; Roberts LR
    Cancer Lett; 2016 Sep; 380(1):163-73. PubMed ID: 27216979
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway.
    Liu Z; Liu J; Chen T; Wang Y; Shi A; Li K; Li X; Qiu B; Zheng L; Zhao L; Shu L; Lian S; Huang S; Zhang Z; Xu Y
    Oncogene; 2022 May; 41(20):2885-2896. PubMed ID: 35428876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.